このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer

Efficacy and Safety of Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Randomized Controlled Trial

The goal of this clinical trial is to learn whether Chinese herbal acupoint application, when added to standard three-drug anti-nausea treatment, can prevent nausea and vomiting caused by chemotherapy in people with breast cancer. The study will also evaluate the safety of the Chinese herbal acupoint application.

The main questions it aims to answer are:

  • Does Chinese herbal acupoint application help participants have less nausea during the first 5 days after chemotherapy?
  • Does it reduce vomiting and the need for additional anti-nausea medicine?
  • Does it affect the impact of chemotherapy-related nausea and vomiting on daily life?
  • What medical problems or side effects occur with the Chinese herbal acupoint application?

Researchers will compare Chinese herbal acupoint application with a sham application. Both groups will receive standard three-drug anti-nausea treatment. The sham application looks and feels similar to the herbal application but does not contain the active herbal ingredients.

Participants will:

  • Receive one cycle of planned chemotherapy and standard three-drug anti-nausea treatment.
  • Receive either the Chinese herbal acupoint application or sham application before chemotherapy. The application will be placed on selected acupuncture points for 4 to 6 hours.
  • Record nausea, vomiting, and use of additional anti-nausea medicine during the first 5 days after chemotherapy.
  • Complete a questionnaire about how nausea and vomiting affect daily life.
  • Have safety follow-up for about 2 weeks after chemotherapy.

調査の概要

研究の種類

介入

入学 (推定)

190

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Zhejiang
      • Hangzhou、Zhejiang、中国、310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥18 years, regardless of sex;
  • Pathologically confirmed operable breast cancer with no prior systemic chemotherapy;
  • Planned to receive one of the following highly emetogenic chemotherapy (HEC) regimens. HEC refers to chemotherapy regimens associated with an expected incidence of vomiting of >90% in the absence of prophylactic antiemetic treatment, including anthracycline/cyclophosphamide-based regimens (AC, TC, or EC) and carboplatin-containing regimens (e.g., TCbH, TCbHP);
  • Planned to receive triple antiemetic prophylaxis consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone. NK-1 receptor antagonists may include fosrolapitant, aprepitant, fosaprepitant, or other approved agents; 5-HT3 receptor antagonists may include palonosetron, ondansetron, or other approved agents;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1
  • Considered by the treating physician to be physically able to undergo and comply with the acupoint application procedure;
  • Adequate major organ function and bone marrow function。

Exclusion Criteria:

  • Skin damage, ulceration, scarring, or severe infection at the intended application sites;
  • Known history of severe allergy to any adhesive tape, patch materials, or herbal/other ingredients used in the study;
  • Significant nausea (VAS ≥25 mm) within 24 hours before chemotherapy that, in the investigator's judgment, is not related to chemotherapy;
  • Refractory vomiting due to non-chemotherapy-related causes, such as complete intestinal obstruction or severe vomiting caused by increased intracranial pressure secondary to brain metastases;
  • Pregnancy or breastfeeding;
  • Concomitant brain metastases, increased intracranial pressure, gastrointestinal obstruction, or other diseases that may cause nausea or vomiting;
  • Severe hepatic, renal, or cardiac dysfunction, or other serious underlying diseases that, in the investigator's judgment, make the participant unsuitable for the study;
  • Planned abdominal or pelvic radiotherapy within 7 days before randomization or during Days 1-7 of chemotherapy;
  • Use of antiemetic medications within 48 hours before chemotherapy, except for the routine prophylactic antiemetic regimen specified in the triple antiemetic therapy, or use of other medications that may affect the assessment of nausea or vomiting;
  • Severe psychiatric illness or cognitive impairment that prevents the participant from understanding the nausea/vomiting assessment scales or - complying with the 4-6-hour acupoint application procedure;
  • Inability to take oral medications;
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Chinese Herbal Acupoint Application

Participants will receive Chinese herbal acupoint application before chemotherapy on Day 1. The herbal paste contains Chinese herbal medicines and will be applied to the Conception Vessel 12 (CV12), Conception Vessel 8 (CV8), and bilateral Pericardium 6 (PC6) acupoints. The patch will remain in place for 4 to 6 hours and will then be removed. Participants will also receive standard three-drug antiemetic treatment as planned for their chemotherapy.

On Day 1, before chemotherapy, participants will receive Chinese herbal acupoint application in addition to standard triple antiemetic therapy. The herbal preparation consists of Ginger-processed Pinellia 90 g, Coptis Rhizome 30 g, Magnoliae Officinalis Cortex 120 g, Ginger-processed Caulis Bambusae in Taeniam 100 g, Evodia fruit 30 g, Dried Tangerine Peel 60 g, and clove flower bud 60 g. The herbs are mixed into powder. For each application, 50 g of herbal powder is mixed with 50 mL normal saline and 50 g medical petrolatum to form a paste. Approximately 1 cm-diameter herbal patches are prepared and applied to the Conception Vessel 12 (CV12), Conception Vessel 8 (CV8), and bilateral Pericardium 6 (PC6) acupoints. The patches are removed after 4-6 hours.

All participants will receive a standard triple antiemetic regimen consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone according to the study protocol and clinical practice. NK-1 receptor antagonists may include fosrolapitant, aprepitant, or fosaprepitant. 5-HT3 receptor antagonists may include palonosetron or ondansetron. The specific antiemetic agent and dosing regimen will be selected according to the chemotherapy regimen and the study protocol.

偽コンパレータ:Sham Acupoint Application

Participants will receive a sham acupoint application before chemotherapy on Day 1. The sham patch will have the same appearance, size, color, smell, and base material as the herbal patch, but will not contain any of the active Chinese herbal ingredients. The sham patch will remain in place for 4 to 6 hours and will then be removed. Participants will also receive standard three-drug antiemetic treatment as planned for their chemotherapy.

All participants will receive a standard triple antiemetic regimen consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone according to the study protocol and clinical practice. NK-1 receptor antagonists may include fosrolapitant, aprepitant, or fosaprepitant. 5-HT3 receptor antagonists may include palonosetron or ondansetron. The specific antiemetic agent and dosing regimen will be selected according to the chemotherapy regimen and the study protocol.

On Day 1, before chemotherapy, participants will receive sham acupoint application in addition to standard triple antiemetic therapy. The sham patches will be identical to the herbal patches in appearance, size, matrix color, odor, and backing material. The sham matrix will contain petrolatum, medical adhesive, and starch, without any active herbal ingredients. The sham patches are not intended to exert pharmacological effects through the skin. The patches will be applied to the Conception Vessel 12 (CV12), Conception Vessel 8 (CV8), and bilateral Pericardium 6 (PC6) acupoints and removed after 4-6 hours.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Participants With No Significant Nausea (NSN) During 0-120 Hours After Chemotherapy
時間枠:0-120 hours after initiation of chemotherapy

No Significant Nausea (NSN) is defined as a nausea score consistently below 25 mm on a 100-mm visual analogue scale (VAS) throughout the 0-120-hour observation period after chemotherapy. The VAS ranges from 0 mm (no nausea) to 100 mm (worst imaginable nausea). The outcome measure is the proportion of participants who meet the criteria for NSN during the overall 0-120-hour observation period.

0-120 hours after initiation of chemotherapy

二次結果の測定

結果測定
メジャーの説明
時間枠
Nausea Severity by VAS During Acute, Delayed, and Overall Periods
時間枠:0-120 hours after initiation of chemotherapy

Nausea severity will be assessed using a 100-mm visual analogue scale (VAS), with 0 mm indicating no nausea and 100 mm indicating the worst imaginable nausea. The maximum and mean VAS scores will be compared between the intervention and control groups during the acute period (0-24 hours), delayed period (24-120 hours), and overall period (0-120 hours) after chemotherapy.

0-120 hours after initiation of chemotherapy
Proportion of Participants With No Significant Nausea During Acute and Delayed Periods
時間枠:0-120 hours after initiation of chemotherapy

The proportion of participants with no significant nausea (NSN) will be compared between the intervention and control groups during the acute period (0-24 hours) and delayed period (24-120 hours) after chemotherapy. NSN is defined as a nausea VAS score consistently below 25 mm throughout the corresponding observation period.

0-120 hours after initiation of chemotherapy
Complete Response (CR) Rate During Acute, Delayed, and Overall Periods
時間枠:0-120 hours after initiation of chemotherapy

The proportion of participants achieving complete response (CR) will be compared between the intervention and control groups during the acute period (0-24 hours), delayed period (24-120 hours), and overall period (0-120 hours) after chemotherapy. CR is defined as no vomiting and no use of rescue antiemetic medication during the corresponding observation period.

0-120 hours after initiation of chemotherapy
Complete Control (CC) Rate During Acute, Delayed, and Overall Periods
時間枠:0-120 hours after initiation of chemotherapy

The proportion of participants achieving complete control (CC) will be compared between the intervention and control groups during the acute period (0-24 hours), delayed period (24-120 hours), and overall period (0-120 hours) after chemotherapy. CC is defined as no vomiting, no use of rescue antiemetic medication, and no significant nausea during the corresponding observation period. No significant nausea is defined as a nausea VAS score consistently below 25 mm throughout the corresponding observation period.

0-120 hours after initiation of chemotherapy
Proportion of Participants With No Impact of CINV on Daily Life
時間枠:120 hours after initiation of chemotherapy

The impact of chemotherapy-induced nausea and vomiting (CINV) on daily life will be assessed using the Functional Living Index-Emesis (FLIE). The proportion of participants with no impact of CINV on daily life will be compared between the intervention and control groups. A total FLIE score of ≥108 is defined as no impact on daily life.

120 hours after initiation of chemotherapy

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Fuming Qiu、Second Affiliated Hospital, Zhejiang University, School of Medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2028年8月1日

研究の完了 (推定)

2028年8月1日

試験登録日

最初に提出

2026年8月24日

QC基準を満たした最初の提出物

2026年9月27日

最初の投稿 (実際)

2026年9月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月27日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する